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Abstract: Inﬂ  ammation is the body’s response to insults, which include infection, trauma, 
and hypersensitivity. The inflammatory response is complex and involves a variety of 
mechanisms to defend against pathogens and repair tissue. In the lung, inﬂ  ammation is usually 
caused by pathogens or by exposure to toxins, pollutants, irritants, and allergens. During 
inﬂ  ammation, numerous types of inﬂ  ammatory cells are activated. Each releases cytokines 
and mediators to modify activities of other inﬂ  ammatory cells. Orchestration of these cells 
and molecules leads to progression of inﬂ  ammation. Clinically, acute inﬂ  ammation is seen in 
pneumonia and acute respiratory distress syndrome (ARDS), whereas chronic inﬂ  ammation is 
represented by asthma and chronic obstructive pulmonary disease (COPD). Because the lung 
is a vital organ for gas exchange, excessive inﬂ  ammation can be life threatening. Because the 
lung is constantly exposed to harmful pathogens, an immediate and intense defense action 
(mainly inﬂ  ammation) is required to eliminate the invaders as early as possible. A delicate 
balance between inﬂ  ammation and anti-inﬂ  ammation is essential for lung homeostasis. A full 
understanding of the underlying mechanisms is vital in the treatment of patients with lung 
inﬂ  ammation. This review focuses on cellular and molecular aspects of lung inﬂ  ammation 
during acute and chronic inﬂ  ammatory states.
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Introduction
Immunity involves innate and adaptive systems. Innate immunity is nonspeciﬁ  c and 
evokes rapid responses, including inﬂ  ammation in face of pathogen insults. Adaptive 
immunity is antigen-speciﬁ  c. It ﬁ  rst detects the speciﬁ  c antigen and then mobilizes 
inﬂ  ammatory cells to target that particular antigen. The innate and adaptive systems 
share components and act in concert to defend against pathogens. The lungs are 
exposed to constant insults from the atmosphere and also to toxic molecules circulating 
through the pulmonary and bronchial vasculature. Elaborate pulmonary defense 
mechanisms are needed for survival. These include ﬁ  rst-line ﬁ  ltration and removal 
systems such as the nasal vibrissae, mucociliary escalator, and cough reﬂ  ex. Secretory 
immunoglobulin A (IgA) in mucus and surfactant produced by alveolar cells also assist 
in immunity against pathogens and smaller particles, while resident immune cells within 
the lung parenchyma await organisms that successfully penetrate the physical barriers. 
Optimal lung defense requires the coordinated action of multiple cell types.
Defense mechanisms in the lung
The airway epithelium is the ﬁ  rst site of contact with inhaled agents. Its epithelial cells 
secrete a variety of substances such as mucins, defensins, lysozyme, lactoferrin. and 
nitric oxide, which nonspeciﬁ  cally shield the respiratory tract from microbial attack.1 
The epithelial cells also produce a number of mediators such as reactive oxygen 
radicals, cytokines (TNF-α, IL-1β, granulocyte/macrophage colony-stimulating factor 
[GM-CSF]), and platelet-activating factor to recruit inﬂ  ammatory cells onto the site of 
inﬂ  ammation.2 The cytokines stimulate arachidonic acid release from membrane lipids, Journal of Inﬂ  ammation Research 2009:2 2
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leading to production of eiconasoids, which further stimulate 
mucus secretion by goblet cells and tissue inﬂ  ammation.
Surfactant lies on the surface of alveoli and contains 
four surfactant proteins (SP A-D). Important for reducing 
lung surface tension, these proteins play a critical role in 
surfactant absorption into the alveolar surface. SP-A and 
SP-D also participate in host defense. They bind bacterial 
surface molecules, modulate leukocyte activity, and lead to 
pathogen opsonization.3
IgA secreted by plasma cells forms an additional 
epithelial protective barrier, which prevents microbial 
adherence to the epithelial surface4 and inhibits certain 
viral infections (influenza and rotavirus) by interfering 
with their assembling processes. It also binds to pathogens, 
causing phagocytosis and antibody-dependent cell-mediated 
cytotoxicity. Selective IgA deﬁ  ciency manifests as atopy and 
recurrent respiratory tract infections. Moreover, patients with 
COPD have decreased IgA levels in saliva and bronchial 
secretions.5 Immunoglobulin E (IgE) induces immediate 
type hypersensitivity in the respiratory tract. It produces 
severe reactions by binding to IgE receptors on the surfaces 
of mast cells, basophils, eosinophils, and B lymphocytes. 
Repeat exposure to the same antigen induces degranulation 
and the release of pro-inﬂ  ammatory mediators, including 
histamine, prostaglandins, leukotrienes, and tryptase.6 These 
increase vascular permeability, bronchoconstriction, and 
inﬂ  ammatory cell inﬁ  ltration.
The foregoing pulmonary defenses maintain sterility 
in the lower respiratory tract, and redundancy in their 
mechanisms ensures overlapping protection from invading 
pathogens.
Inﬂ  ammatory cells
Dendritic cells are antigen-presenting cells (APCs), which 
stimulate naïve T cell proliferation. Dendritic cells and 
macrophages are the ﬁ  rst line of defense in recognizing 
various pathogens. Originating in bone marrow, dendritic 
cells reach tissues through blood circulation and, in the lung, 
reside in and below the airway epithelium, the alveolar septa, 
pulmonary capillaries, and airway spaces.7 Once the dendritic 
cell identiﬁ  es, ingests, and processes an antigen, it migrates to 
the lymph nodes and presents the antigen to resident T cells, 
inducing the immune response.
Macrophages reside in the airways, alveoli, and lung 
interstitium, or migrate into the lung microvasculature. 
Their role is essential in modulating acute and chronic 
inﬂ  ammatory responses, but although macrophages can 
proliferate within the lung, their number is not adequate 
to ﬁ  ght infection.8 Macrophage function is augmented by 
dendritic cells. Together they are capable of phagocytosing 
bacteria, particulates, and apoptotic cells. However, 
macrophages are the main source of cytokines, chemokines, 
and other inﬂ  ammatory mediators that propagate or suppress 
the immune response. Following an insult, macrophages and 
epithelial cells secrete chemokines and cytokines, promoting 
neutrophil accumulation and local inﬂ  ammation.9
Neutrophils provide second-line defense. They are the 
ﬁ  rst cells to be recruited to sites of infection or injury, and 
attack fungi, protozoa, bacteria, viruses, and tumor cells. 
During pulmonary infection, neutrophils migrate out of 
the pulmonary capillaries and into the air spaces.10 After 
phagocytosis, neutrophils kill ingested microbes with 
reactive oxygen species, antimicrobial proteins (bacteri-
cidal permeability-inducing protein and lactoferrin), and 
degradative enzymes (elastase). Deﬁ  cits in neutrophil 
quantity (neutropenia) and quality (chronic granuloma-
tous disease) predispose patients to opportunistic lung 
infections.
Lymphocytes are found throughout the airway and 
lung parenchyma. There are two major populations of 
lymphocytes: thymus-dependent T cells and bone marrow-
dependent B cells. T lymphocytes provide cell-mediated 
immunity, while B lymphocytes produce humoral immune 
responses by synthesizing antibodies (immunoglobulins). 
T lymphocytes have two major subsets: CD4+ and CD8+. 
CD4+ T lymphocytes are also known as helper T cells, 
which are further subdivided into Th1 and Th2, with dif-
ferent cytokine proﬁ  les. Th1 cells drive cellular immunity. 
Th1 cytokines (interferon gamma, TNF-α) produce the 
pro-inﬂ  ammatory responses to ﬁ  ght viruses and other intra-
cellular parasites, and to eliminate cancer cells. Excessive 
pro-inﬂ  ammatory responses can lead to uncontrolled tissue 
damage. Th2 cells drive humoral immunity to up regulate 
antibody production to fight extracellular organisms. 
Th2 cytokines (IL-4, IL-5, IL-9, and IL-13) promote IgE and 
eosinophilic responses in atopy. Excessive Th2 responses 
will counteract the Th1-mediated anti-microbial actions 
(Figure 1). Optimally, a balanced Th1 and Th2 response is 
suited to the immune challenge, and a dysregulated response 
is linked to a variety of chronic inﬂ  ammatory conditions like 
asthma and chronic bronchitis.11 CD8+ T cells are mainly 
cytotoxic T cells. They secrete molecules that kill infected 
cells and tumor cells. In addition, there is a natural killer cell 
(NK cell) subset of T cells with no antigen-speciﬁ  c recep-
tors.12 Another subset of T cells, named NKT cells, which 
have the properties of NK cells, are important in combating Journal of Inﬂ  ammation Research 2009:2 3
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bacteria, protozoa, and viruses.13 Furthermore, there are 
regulatory T cells, which suppress the other lymphocytes. 
During the immune response, some antigen-activated B cells 
and T cells differentiate into memory cells, producing long-
lasting immunity.
Mast cells reside near blood vessels and nerves in tissues 
throughout the body. They may be activated by a variety 
of stimuli through various receptors. In the airways, mast 
cells have receptors for IgE. Once activated, the mast cells 
produce histamine, leukotrienes, proteases, cytokines, 
chemokines, and other substances that cause immediate 
airway inflammation, leading to asthma symptoms. 
Secreted cytokine and chemokine may contribute to 
chronic airway inﬂ  ammation. Mast cells function in innate 
immunity, host defense against parasites, tissue repair, and 
angiogenesis.14
Eosinophils, the least common white blood cells, are 
often associated with parasite infections, allergic diseases 
(such as asthma), chronic lung inﬂ  ammatory states, and 
hypereosinophilic syndrome. The eosinophil is an important 
source of major basic proteins, lipid mediators, cytokines, and 
growth factors, and also secretes mast cell stem cell factor, 
essential for mast cell growth, activation, chemotaxis, and 
degranulation.15
Although the inflammatory cells take center stage, 
epithelial, endothelial and mesenchymal cells also participate 
in the inﬂ  ammatory process.2,16
Cytokines
Cytokines are secreted polypeptides produced by all kinds 
of cells. They have autocrine, paracrine, or endocrine func-
tions to regulate immunity and inﬂ  ammation. Binding to 
speciﬁ  c membrane receptors, cytokines signal the cell via 
secondary messengers, increasing or decreasing expres-
sion of membrane proteins, as well as cell proliferation 
and secretion. Different cell types can secrete the same 
cytokine and a given cytokine can act on several cell 
types (pleiotropy) to stimulate or suppress other cytokines. 
Cytokines that act as chemotactic agents or chemoattrac-
tants for other cells are known as chemokines. Cytokines 
are redundant, that is, similar functions can be produced 
by different cytokines that act either synergistically or 
antagonistically.
Cytokines can be categorized as pro-inﬂ  ammatory or anti-
inﬂ  ammatory. Major pro-inﬂ  ammatory cytokines are TNF-α, 
IL-1β, IL-6, IL-8, and IFNγ. They activate the immune 
system and participate in the acute inﬂ  ammatory response. 
TNF-α and IL-1β are the most important pro-inﬂ  ammatory 
PAMPs
PRRs
APC
APC presents antigen to 
naïve T cells (Th0)  
in LN or BALT
Th1 cells  Th2 cells 
IFN-γ, TNF, IL-1, 12 
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IL-4, 5, 6, 10, 13 
Humoral immune 
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IFN-γ  inhibits Th2 resp. 
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Figure 1 Immune response to lung infections.
Abbreviations: APC, antigen presenting cell; BALT, bronchial-associated lymphoid tissues; LN, lymph nodes; PAMPs, pathogen-associated molecular patterns; PRRs, pattern 
recognition receptors; resp, response;   Th0, naïve T cells;   Th1, type 1 helper T cells, Th2 cells, type 2 helper T cells.Journal of Inﬂ  ammation Research 2009:2 4
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cytokines and stimulate antigen presentation, adhesion 
molecule expression on endothelial cells, inﬂ  ammatory cell 
activity, and expression of matrix-degrading enzymes, like 
collagenase. Major anti-inﬂ  ammatory cytokines include 
IL-10, TGF-β, and IL-1ra (a natural IL-1 receptor antagonist). 
Alveolar macrophages secrete the anti-inﬂ  ammatory cyto-
kines to down regulate the inﬂ  ammatory response in the 
lungs.17,18 Receptors for TGF-β are present on virtually all 
cells. TGF promotes wound healing and scar formation. 
IL-10 inhibits the production of pro-inﬂ  ammatory cytokines 
by T cells, NK cells, and monocytes.19 Increasing evidence 
indicates that dysregulation of cytokines is an important step 
in many pulmonary diseases. For example, allergens stimu-
late Th2 cells. In allergic asthma, APCs activate Th2 cells 
to produce IL-4 and IL-13, which in turn stimulate B cells 
to produce IgE and subsequent mast cell degranulation. 
Activation of Th2 cells also causes IL-5 production, which 
stimulates eosinophils.20 Mediators released by mast cells 
and eosinophils produce an asthmatic attack. Many cyto-
kines are associated with COPD, including TNF-α, IFN-γ, 
IL-1β, IL-6, and GM-CSF.21 In ARDS, pro-inﬂ  ammatory 
cytokines (TNF-α and IL-1β) are increased 22 and the incre-
ment of anti-inﬂ  ammatory cytokines like IL-10 may not keep 
up with their production. It has been reported that IL-10 is 
lower in ARDS than in critically ill non-ARDS patients.23 
The imbalance of the pro- and anti-inﬂ  ammatory cytokines 
may promote the disease.
Acute pulmonary inﬂ  ammation
Macroscopically, inﬂ  ammation is characterized by redness, 
swelling, heat, pain, and loss of function. Microscopically, 
it is exhibited by vasodilation, increased vascular perme-
ability, and inﬂ  ammatory cell inﬁ  ltration. Inﬂ  ammatory 
responses are to destroy and remove, as well as to wall off 
and conﬁ  ne the injurious agents. Furthermore, inﬂ  ammation 
stimulates the immune response to promote recovery. Acute 
lung inﬂ  ammation is dominated by neutrophils, whereas 
chronic reactions involve mainly macrophages and lympho-
cytes. ARDS is an example of acute inﬂ  ammation not only 
persisting but also becoming ampliﬁ  ed to involve the entire 
organ. During acute lung insult, endothelial cells are activated 
to express chemotactic factors, including endothelial-derived 
adhesion molecules that lead to attachment and diapedesis 
of leukocytes in the region. A resulting chemotactic gradient 
ﬁ  rst directs neutrophil migration and then further chemokine 
production to orchestrate formation of granulation tissue 
comprising cellular matrix, ﬁ  broblasts, endothelial cells, 
and leukocytes.
Bacterial infections
When the lung is exposed to minimal bacterial loads, 
pathogen clearance operates through innate defenses and the 
event is generally subclinical. Acute infection results when 
higher loads of bacteria overcome the local defenses, leading 
to acute inﬂ  ammation involving both innate and adaptive 
defenses. Bacterial colonization results from abnormal innate 
defenses, establishing an equilibrium between bacterial 
replication and clearance. Chronic infection occurs when 
marked a inﬂ  ammatory response generated by host defense 
mechanisms fails to clear the bacteria, with continued tissue 
destruction.24
When inhaled in a signiﬁ  cant load, bacteria overcome 
primary host defenses by releasing ciliary toxins, pneumolysin, 
endotoxin, and IgA proteases, thereby disrupting mucociliary 
clearance.25 Ultimately, bacteria adhere to the epithelium. In 
response, dendritic cells, alveolar macrophages, and epithelial 
cells are activated as pathogen markers are identiﬁ  ed through 
toll like receptors (TLRs). Recognition of the pathogen initiates 
inﬂ  ammation, which progresses through four phases: initiation, 
ampliﬁ  cation, phagocytosis, and resolution.
Initiation
TLRs are membrane-bound pattern-recognition receptors 
(PRRs). They recognize speciﬁ  c conserved molecular patterns 
broadly shared by pathogens, known as pathogen-associated 
molecular patterns (PAMPs). PAMPs are molecules essen-
tial for microorganism survival, and innate and adaptive 
immunity ensue when they are engaged by PRRs.4 There 
are at least 10 types of TLRs that recognize microbes on the 
cell surface or in endosomes. TLR-4 recognizes endotoxins 
and lipopolysaccharide-binding proteins from gram-negative 
bacteria; TLR-2 recognizes gram-positive bacteria and 
peptidoglycans.26 In addition, cytosolic PRRs consist mainly 
of nucleotide oligomerization domain (NOD)-like receptors 
(NLRs) and function as regulators of innate immune response 
against microbial pathogens. Stimulation of NOD1 and NOD2, 
two prototypic NLRs, activates mitogen-activated protein 
kinases and NF-κΒ.27 The NLRs recognize speciﬁ  c compo-
nents of bacteria and form a cytoplasmic signaling complex 
with other proteins known as the inﬂ  ammasome.28 In some 
cells, inﬂ  ammasome activation may lead to rapid host cell 
death (pyroptosis), which may protect the host by preventing 
bacterial replication.
Ampliﬁ  cation
After PAMPs are recognized, cell activation increases 
transcription factors like NF-κβ, producing growth factors, Journal of Inﬂ  ammation Research 2009:2 5
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chemokines, adhesion molecules and pro-inflammatory 
cytokines including IL-8 and TNF-α.29 IL-8 acts as a 
neutrophil chemotactic agent, and TNF-α increases expres-
sion of lung capillary endothelial cell adhesion molecules30 
for increased neutrophil adhesion. Activated neutrophils 
release more IL-8,31 which in turn increases neutrophil 
recruitment. Also, elastase from activated neutrophils induces 
epithelial IL-8 production.32 While neutrophils and alveolar 
macrophages are combating the pathogen in a nonspeciﬁ  c 
way, dendritic cells present the T lymphocytes with the 
foreign antigen and cause either a Th1 or Th2 response. The 
activated T cells and B cells (producing antibodies) follow 
to defend the body against the bacterial attack. Growth 
factors and cytokines released from activated T cells further 
stimulate the macrophages.
Phagocytosis
After successfully evading mechanical barriers and ciliary 
removal, and surviving the actions of surfactants and 
antibodies, bacteria may encounter complement proteins. 
Complements facilitate recognition by alveolar macrophages 
of bacteria through PRRs and prepare bacteria for phagocy-
tosis. At least two additional mechanisms can be activated 
to enhance killing and clearance of the microbe.33 The ﬁ  rst 
involves alveolar macrophages and their ability to liberate 
chemotactic factors that attract nearby neutrophils and initiate 
inﬂ  ammatory responses. The second occurs when the bacteria 
trigger T cells, to release cytokines that stimulate the phago-
cytic and bactericidal capacity of alveolar macrophages.
Resolution
Resolution occurs after a successful host response. Complete 
bacterial phagocytosis, and killing by reactive oxygen species, 
bacteriocidal permeability-inducing protein, lactoferrin, 
elastase, and neutrophil extracellular trap,34 down regulates 
the host defense system. Resolving lung inﬂ  ammation depends 
upon apoptosis as well as timely and adequate removal of 
acute inﬂ  ammatory cells by macrophages. During apoptosis, 
neutrophils and eosinophils undergo surface changes enabling 
phagocytes to recognize and ingest them. The apoptotic 
process is modulated through extracellular signaling. For 
example, neutrophils cultured in the bronchial alveolar lavage 
ﬂ  uid from ARDS patients have a longer lifespan than those 
from patients with normal lungs. Pro-inﬂ  ammatory cytokines 
such as GM-CSF may be responsible for apoptosis delay.35 In 
some circumstances, apoptosis of eosinophils and neutrophils 
is conversely regulated. For example, dexamethasone enhances 
apoptosis of eosinophils, but inhibits that of neutrophils, 
prolonging neutrophil viability.5 Resolution of inﬂ  ammation 
not only depends on the removal of apoptotic cells but also on 
suppression of inﬂ  ammatory mediator production.6 Incomplete 
resolution leads to chronic inﬂ  ammation.
Viral infections
Viruses activate the innate immune system through cell 
surface and cytosolic PRRs, which detect viral components 
(especially nucleic acids). TLR-3 recognizes double-stranded 
RNA viruses, while TLR-7 and TLR-8 detect single-stranded 
RNA viruses. The activated immune cells synthesize antiviral 
type I interferon (IFN), pro-inﬂ  ammatory cytokines, and 
chemokines including TNF-α, IL-1β, IL-6, IL-8, IL-12, and 
monocyte chemoattractant protein 1.36
Respiratory virus infections elicit primarily a Th1 type 
response, which is dominated by IFNγ production. Th2 
responses are ineffective or even detrimental.37 CD8+ cytotoxic 
T cells as well as NK cells play a key role in viral clearance, 
although neutralizing antibody is also generated late in a 
primary infection by inﬂ  uenza and parainﬂ  uenza.37 In a second-
ary infection, both CD4+ and CD8+ T cells respond promptly. 
Large populations of memory T cells persist in the airways 
and lung parenchyma and decrease gradually over several 
months, and then stabilize at a low level. This progressive loss 
correlates with a decline in protective cellular immunity, sug-
gesting a critical role of memory T cells in the lung. Viruses are 
also responsible for episodes of exacerbations of COPD and 
asthma, where they increase the airway inﬂ  ammation (acute 
exacerbation or chronic inﬂ  ammation).
Parasitic infections
Many protozoa and helminthes involve the respiratory system. 
Our understanding of the role of TLR in parasitic diseases is 
just beginning. For example, TLR-2 and TLR-9 are associated 
with malarial infection,38 whereas TLR-4 involves contain-
ment of leishmaniasis.39 Protozoa vary greatly and stimulate 
distinct immune responses. Protozoa may be phagocytized 
by macrophages, but many are resistant and may replicate 
within macrophages.40 In resolving Leishmania infections, 
a protective Th1 response by host cells leads to macrophage 
activation to kill the organism.41 PRRs are also used to detect 
molecules on protozoa, which leads to their killing by comple-
ment activation and phagocytosis.42
Helminthes usually produce Th2 responses, with secretion 
of IgE and activation of eosinophils, basophils, and mast cells. 
In contrast, bacteria and viruses typically evoke IFNγ domi-
nant Th1 response with activation of CD8+ cytotoxic T cells, 
neutrophils, and macrophages. Activated macrophages engulf Journal of Inﬂ  ammation Research 2009:2 6
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and destroy microorganisms through expression of inducible 
nitric oxide synthesis (iNOS). However, in Th2 response 
to helminthes, macrophage activation is triggered by IL-4, 
IL-10, IL-13, and IL-21, and does not express iNOS.43 The 
activated macrophages and eosinophils may contribute to the 
healing of damaged tissue caused by invasive helminthes. 
Neutrophils are rapidly recruited in response to invasive 
helminthes. Eosinophils migrate to the site of infection where 
they release mediators, help in tissue remodeling, and assist 
neutrophils to kill the organism.43 IgE is also very important. 
It forms immune complexes with the organisms that are then 
eliminated by macrophages.
Chronic pulmonary inﬂ  ammation
Chronic inﬂ  ammation occurs when resolution of acute inﬂ  am-
mation is incomplete. Chronic inﬂ  ammatory responses clear 
necrotic debris and apoptotic cells from acute inﬂ  ammation; 
defend against and prevent the spread of persistent infec-
tions; and heal and repair the lung tissue damage. The major 
cells involved are macrophages and lymphocytes. Cytokines 
are produced by a variety of immune and nonimmune cells. 
The production of these cytokines can dictate the extent and 
type of the inﬂ  ammatory response. In chronic lung inﬂ  am-
mation, proﬁ  brotic and immunoregulatory Th2 cytokines 
dominate. Chemokines play a pivotal role in regulating cell 
trafﬁ  cking, angiogenesis, and the inﬂ  ammatory response. 
They mediate neutrophil inﬁ  ltration into the lung parenchyma 
and pleural space by binding to receptors on neutrophils, 
lymphocytes, monocytes, and dendritic cells.44,45 In mice, 
inoculation of the airways with Pseudomonas leads to per-
sistent release of chemokines and time-dependent neutrophil 
inﬂ  ux.46 In interstitial pulmonary ﬁ  brosis (IPF), chemokine 
(IL-8) is signiﬁ  cantly elevated and correlates with the pres-
ence of neutrophils in bronchoalveolar lavage ﬂ  uid. As men-
tioned above, apoptosis plays an important role in chronic 
lung inﬂ  ammation. During chronic inﬂ  ammation, abnormal 
function of inducer or suppressor genes decreases apoptosis 
of immune cells. This leads to prolongation of inﬂ  ammatory 
cell inﬁ  ltration of the lungs.
Chronic airway inﬂ  ammation is characteristic in both 
asthma and COPD, yet there are marked differences in 
the inﬂ  ammatory cells involved. Airway eosinophils is 
Table 1 Mechanisms in different types of infection
Response Examples
Viruses PRRs recognize PAMPs Æ NF-κB activation Æ ↑synthesis 
of antiviral type 1 IFNs (α, β) and inﬂ  ammatory cytokines 
(TNF-α, MCP1, IL-6, 8, 12)36
Primary infection:
CD8+   T cells clearing up the infection37
Secondary infection:
1) Recruitment of circulating memory T cells (CD8+, CD4+) 
(antigen nonspeciﬁ  c; IFN-γ mechanism)
2) Antigen-speciﬁ  c T cells produced by proliferation 
of quiescent central memory T cells (CD8+) in BALT68
ssRNA viruses:
1) Inﬂ  uenza A:
2) RSV:
dsDNA viruses
1) Adenovirus:
2) HSV:
TLR369 and TLR770
TLR471
CDS72 Æ IFN, IL-6, TNF-α synthesis
TLR2,73 TLR974
Bacteria PRRs (TLR2 for Gm+ peptidoglycan; TLR4 for Gm- LPS) 
on APCs recognize PAMPs Æ NF-κB activation Æ TNF-α, 
IL-1, 8,24 Æ neutrophil chemotaxis Æ phagocytosis Æ 
resolution
Staphylococcus aureus 
Pseudomonas aeruginosa
Streptococcus pneumoniae
Klebsiella pneumoniae
Mycobacteria
TLR275
TLR5 recognizes Flagellin76 Alveolar 
macrophages (TLR2 less important)77
TLR4 Æ CD4+   T cells → IL-17 Æ 
epithelial cells→chemokines78,79
TLR2, 480 Æ cytotoxic CD8+ T cell 
activation and IFN-γ production.81
Parasites Three mechanisms involve the respiratory system:82 
stimulation of hypersensitivity during life cycle
direct parenchymal or pleural invasion migration from 
infected organs 
Parasite speciﬁ  c-IgE form immune complexes which are 
removed by macrophages82 Protozoa vary in structure and 
bioche-mistry Æ distinct immune responses. Helminths Æ 
Th2 response and alternate macrophage activation83 Major: 
eosinophils, basophils, mast cells Minor: neutrophils43
1) Protozoa:
Leishmania
Plasmodium
2) Helminths:
Schistosoma
TLR484
TLR2, 938 Æ NK cells, NKT cells to 
produce IFN-γ85
Parasite eggs→granulomatous 
response via TLR 2,382
Abbreviations: APCs, antigen presenting cells;  BALT, bronchial-associated lymphoid tissues;  dsDNA, double-stranded DNA;  HSV, herpes simplex virus; IFN, interferon; MCP1, 
monocyte chemoattractant protein 1; NK cells, natural killer cells; PAMPs, pathogen-associated molecular patterns; PRRs, pattern recognition receptors; RSV, respiratory 
syncytial virus; ssRNA, single-stranded RNA; TLR, Toll-like receptors.Journal of Inﬂ  ammation Research 2009:2 7
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prominent in asthma, but not in COPD except during acute 
exacerbations.47,48 Apoptosis is inversely correlated with 
the clinical severity of asthma. Asthmatics show more 
submucosal “nonapoptotic” eosinophils than patients with 
chronic bronchitis or normal subjects. Bronchial biopsy 
specimens from asthmatic subjects reveal a higher inﬁ  ltration 
of eosinophils expressing anti apoptotic genes (bcl-2) than 
those expressing pro-apoptotic oncogenes (p53).49 Decreased 
T cell apoptosis in asthma may lead to its increased number. 
CD4+ T cells are more evident in asthma, whereas CD8+ 
T cells are predominant in COPD.50 Moreover, CD8+ T cells 
are higher in smokers than asthmatics.51,52 In smokers, the 
severity of airﬂ  ow limitation correlates with the number 
of neutrophils, macrophages, and NK lymphocytes in 
bronchoalveloar lavage ﬂ  uid.51 Inﬂ  ammation in asthma is 
only in the airways, but in COPD, inﬂ  ammation extends from 
the peripheral airways down to the lung parenchyma.
Chronic bronchitis is characterized by airﬂ  ow obstruction, 
mucus hypersecretion, and inﬂ  ammation throughout the 
lungs. Neutrophils predominate in the airway lumen, 
although mononuclear cells, macrophages, CD8+ T cells 
and B cells inﬁ  ltrate the larger airway walls.53 Plausibly, the 
severity of airway inﬂ  ammation can be related to the severity 
of the disease 51 and is a better pathologic marker of chronic 
bronchitis than submucosal gland hypertrophy.
Th2 response is involved in chronic ﬁ  broproliferative 
disorders. Suppression of Th1 response or exaggerated Th2 
response can lead to IPF.54 Interstitial lung diseases are 
Table 2 Pathology and immune mechanisms in some common respiratory diseases
Pathophysiology Pathology Cells Mediators
Acute
Pneumonia Parenchymal 
inﬂ  ammation
Lobar/patchy 
consolidation
Viral, bacterial, parasitic
Invasion→ recognition→
Inﬂ  ammatory ampliﬁ  cation→
phagocytosis→ resolution
APC,34 neutrophil, eosinophil 
(parasites)
Macrophage (mycobacteria) 
Th1/Th2 response
IL-8, TNF-α, NETs4
IL-1β
ARDS/ALI PaO2/FiO2  200 (≤300 ALI)
PCWP  18 mmHg
Bilateral inﬁ  ltrates
Sepsis, trauma, aspiration
Early phase:↑capillary 
permeability
alveolar edema and necrosis
↓surfactant: alveolar collapse
Late phase: ﬁ  brosis
Neutrophil86
Macrophage87
Type I and II Pneumocytes88
Fibroblast, Endothelial cell
Lipid mediators, 
Proteases,
NF-κB, Growth 
factors89
IL-1β, TNF-α90
Chronic
COPD ↑TLC, RV, ↓ VC, FEV1/FVC
↓ DLCO
Alveolar apoptosis91
Poor phagocytosis 
of apoptotic
neutrophils→necrosis→↑NE 
release
↓VEGF:92 Chronic 
parenchymal and
airway inﬂ  ammation
Macrophage
Neutrophil
CD8+ T cell
Airway epithelial cell
MMP12, 8, 9, cathepsin 
S,L,G93
NE, IFN-γ, MIG94
TGF-β, EGF, PDGF95
Asthma ↑ FEV1  12%/200 ml 
after BD
↓ FEV1/FVC
Airway inﬂ  ammation96
Fibrosis and SMC hyperplasia
↓ tolerogenic immune 
response
Eosinophil,97 Mast Cell,
Neutrophil98
Macrophage, DC, Airway SMC
Epithelial cell, Fibroblast99
CD4+ T cells,100 Basophil101
↓ IL-10,102 TGF-β103
↑ IL-17104 and IL-4, 5, 
9, 1315
IPF ↓FEV1, FVC, TLC, RV, DLCO
↔ FEV1/FVC
Epithelial→mesenchymal 
transition105
Injury→mediator release: 
ﬁ  brosis106
↑ angiogenesis
Damaged basement 
membrane107
Fibroblast
Airway epithelial cell
Type II pnemocyte107
IL-8, TNF-α, TGF-β108,109
IL-4, 5, 13110,111
Abbreviations: ALI,  Acute lung injury;   APC, antigen presenting cells;   ARDS, Acute respiratory distress syndrome; BD, Bronchodilator; COPD, Chronic obstructive pulmonary 
disease; DC, Dendritic cell; DLCO, Diffusing capacity of lung for Carbon monoxide; EGF, Endothelial growth factor; FEV1, Forced expiratory  volume in 1 sec; FiO2, Fraction of 
inspired oxygen; FVC, Forced vital capacity; IFN-γ, Interferon gamma; IL, Interleukin; MIG, Monokine induced by gamma interferon; MMP, Matrix metalloproteinases; NE, Neu-
trophil elastase; NETs, Neutrophil extracellular traps; NF-κβ, Nuclear factor kappa beta; PaO2, Partial pressure of arterial oxygen;  PCWP, Pulmonary capillary wedge pressure; 
PDGF, Platelet derived growth factor; RV, Residual volume; SMC, Smooth muscle cell;   TGF-β, Transforming growth factor beta; TLC, Total lung capacity; TNF-α,   Tumor necrosis 
factor alpha; Treg, Regulatory T cell;   VC, Vital capacity;  VEGF,  Vascular endothelial growth factor.Journal of Inﬂ  ammation Research 2009:2 8
Moldoveanu et al
characterized by proliferation of ﬁ  broblasts and production 
of cytokines, chemokines, and glycosaminoglycans. These 
cytokines mediate the generation of tissue collagenase, 
gelatinase, and PGE2, which augment extracellular collagen 
and ﬁ  brinous matrix degradation. IL-1α and IL-1β stimulate 
production of type I and III collagen from ﬁ  broblasts and type 
IV collagen from epithelial cells. Moreover, production of 
PGE2 inhibits ﬁ  broblast proliferation.
Th1 primarily involves granulomatous inﬂ  ammation. 
Sarcoidosis is the best known of these, although tuberculo-
sis and hypersensitivity pneumonitis are also important.55,56 
Th2 drives eosinophilic granualomatous diseases, like Churg-
Strauss vasculitis.57 Although the clinical presentation of 
these diseases may be different, the inﬂ  ammatory processes 
possess a similar propagation of events in the pathogenesis 
of their development.
Recently, GITR (glucocorticoid-induced TNF receptor-
related protein) was found to be important in acute as well 
as chronic inﬂ  ammation, and is closely associated with the 
development of pulmonary ﬁ  brosis. Neutrophil inﬁ  ltration, 
pro-inﬂ  ammatory cytokines, and toxic oxygen species are 
decreased in the pleural ﬂ  uid in GITR-/- pleurisy mice,58 
and neutrophils are decreased in the bronchoalveolar lavage 
ﬂ  uid of GITR-/- bleomycin-induced pulmonary ﬁ  brosis 
mice. Moreover, lung histology also showed less ﬁ  brosis in 
GITR-/-mice.58
Regulation of lung inﬂ  ammation
The lung provides a huge surface for gas exchange 
and pathogen contact. While a forceful innate immune 
response, such as inﬂ  ammation, is needed to ﬁ  ght off the 
harmful invaders, effective regulation to suppress the 
inﬂ  ammatory processes and limit inﬂ  ammation-induced 
damage is also necessary to maintain homeostasis. Such 
regulatory mechanisms are in place to protect lung function. 
For example, activation of TLRs may suppress Th1- and 
Th2- mediated lung inﬂ  ammation, thus providing negative 
feedback to prevent excessive lung inﬂ  ammation.59 In addi-
tion, cytokines produced by inﬂ  ammatory cells (IL-1060 
and TGF-β61) can down regulate inﬂ  ammatory cytokine 
production and inﬂ  ammatory response. The lungs provide 
organ-speciﬁ  c regulatory strategies to prevent excessive 
inﬂ  ammation during microbial invasion. For example, Type 
II epithelial cells in the lung communicate with alveolar mac-
rophages, providing tonic inhibitory effects through TGF-β to 
limit potential adaptive immune-induced lung inﬂ  ammation.1 
Recent evidence indicates that neural immune interaction 
may play an important role in controlling inﬂ  ammation in 
a variety of diseases.62 Such control involves the peripheral 
and central nervous systems to regulate the body’s reaction. 
Sensory neurons in the airways may provide a sensing 
mechanism to detect the inﬂ  ammatory intensity in the lung 
for lung-brain communication. Indeed, sensory neurons in 
the lung are activated during acute lung injury.63 In addition, 
pro-inﬂ  ammatory cytokines and mediators, and TLR ligands 
can stimulate airway sensory neurons,64 which may initiate a 
reﬂ  ex to suppress production of pro-inﬂ  ammatory cytokines.65 
These negative feedback regulatory mechanisms are impor-
tant in control of inﬂ  ammatory intensity. On the other hand, 
activation of sensory afferents may release neuropeptides, 
which can induce neurogenic inﬂ  ammation to intensify the 
inﬂ  ammatory response.66,67
Concluding remarks
Inﬂ  ammation is an important feature of many pulmonary 
diseases such as pneumonia, ARDS, asthma, and COPD. 
Varied and disparate strategies have been adopted to 
intervene in pulmonary immune responses. In addition to 
looking at the cytokines, cytokine receptors, and cell-surface 
molecules, cellular signal transduction and gene activation 
have been targeted for therapy. It is apparent that to 
understand the mechanism of upcoming future modalities of 
treatment, the physician should have a basic understanding 
of the underlying cellular mechanisms of inﬂ  ammation.
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